Cardiovascular

Researchers found evidence correlating toxic air pollutants to increased respiratory and cardiovascular death rates.

Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.

People who have better cardiovascular health, as scored by the American Heart Association's Life's Simple 7, at age 50 have a lower risk of developing dementia over the next 25 years, according to a new study.

Patients were 16% more likely to have a cardiovascular event if their prescription was rejected and 21% more likely to have a cardiovascular event if they did not fill their prescription.

Following an executive order from President Donald Trump, HHS announced the launch of Advancing American Kidney Health, an initiative to improve the health of the 37 million Americans living with kidney disease, by releasing 5 new payment models.

Coverage of DECLARE, CARMELINA, and other studies that highlight the connection between diabetes and renal outcomes

Here are the top 5 articles for the month of June.

Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous cardiovascular disease.

Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.

The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.

Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.

Merck's Center for Observational and Real-World Evidence has spent several years gathering evidence on clinical inertia and is now working on solutions to overcome it at the point of care.

There was something for everyone at the American Diabetes Association (ADA) Scientific Sessions, held June 7-11, 2019, in San Francisco, California.

The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.

The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with standard treatment using sulfonylurea and insulin for patients with type 2 diabetes who have difficulty maintaining glycated hemoglobin of seven percent or less on metformin alone.

Heart disease was the number one reason for “excess deaths” after Hurricane Maria struck Puerto Rico in September 2017.

For endocrinologists, a cardiologist, a diabetes educator, and a room full of fellow health workers, the cost of doing nothing—not just to treat diabetes, but also to prevent it— is what feeds into the exorbitant cost of the disease, according to presentations and a panel at the inaugural meeting of the Institute for Value Based Medicine (IVBM) in Diabetes, an initiative of The American Journal of Managed Care®.

The results come as US professional societies are updating primary prevention guidelines in cardiology.

Previous research overstated the generalizability of the Exenatide Study of Cardiovascular Event Lowering trial results by omitting the restriction on the percentage of patients without a prior cardiovascular event.

The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.

Based on recently published results of the REDUCE-IT study, pharmacuetical company Amarin has submitted a supplemental new drug application (sNDA) to the FDA for an expanded label for its leading drug Vascepa. Also, the American Diabetes Association has included the drug in a mid-year update to its 2019 Standards of Medical Care in Diabetes.

Panelists discuss what PCSK9 inhibitors are, the evidence to support them, and challenges with operationalizing them in practice.